Lab Med Qual Assur.  2024 Jun;46(2):73-77. 10.15263/jlmqa.2024.46.2.73.

Annual Report of the Korean External Quality Assessment Service on General Transfusion Medicine and General Transfusion Antibody Tests (2023)

• Kim HJ
• Kim JS
• Seo SW
• Kim H
• Cho D
• Ko DH

• KMID: 2557221
• DOI: http://doi.org/10.15263/jlmqa.2024.46.2.73

Abstract

This report aimed to provide a summary of the 2023 survey results on the external quality assessment (EQA) scheme for the general transfusion medicine test and general transfusion antibody test programs in Korea. Proficiency testing materials were prepared at the Asan Medical Center for biannual distribution to participating laboratories. The accuracy rates and number of participating laboratories were as follows: ABO typing, 99.8%–100.0% (n=940, n=940); RhD typing, 99.8%–100.0% (n=924, n=918); crossmatching, 95.6%–99.4% (n=802, n=825); unexpected antibody screening, 99.4–100.0% (n=358, n=358); direct antiglobulin test (DAT) using a polyspecific reagent, 99.3%–100.0% (n=296, n=292); DAT using anti-immuno globulin G monospecific reagent, 100.0% (n=76, n=76); and DAT using antiC3d monospecific reagent, 97.3%–100.0% (n=73, n=73). The 2023 EQA scheme for transfusion medicine program has improved and maintained the standards of the participating laboratories.

Keyword

Transfusion medicine; Quality improvement; Laboratory profi ciency testing